Type 2 Diabetes and ADP Receptor Blocker Therapy

Table 1

ADP receptor blockers in current clinical practice.

Drug	Route of administration	Bioavailability	Receptor inhibition	Time to peak platelet inhibition	Clinical application	Interactions with T2D
Clopidogrel	Oral	Prodrug	Irreversible	Highly variable	PCI, arterial interventions, ACS, stroke, and secondary prevention	Repeatedly proven
Prasugrel	Oral	Prodrug	Irreversible	2 hours	ACS with PCI	Not explicitly proven
Ticagrelor	Oral	Direct-acting	Reversible	2 hours	ACS	Probably none
Cangrelor	Intravenous	Direct-acting	Reversible	30 minutes	PCI	Not studied

ACS: acute coronary syndromes, PCI: percutaneous coronary intervention, T2D: type 2 diabetes.